Invivoscribe, Inc.
San Diego, CA
- UEI
- R1EVMK8MEZS9
- CAGE
- 455H0
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 10222 Barnes Canyon Rd #100, San Diego, CA 92121, USA
- Website
- invivoscribe.com
- Founded
- 1995
- Employees
- 251-1K
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $114,292 |
| FY2025 | $72,167 |
| FY2024 | $87,286 |
| FY2023 | $49,280 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $114,292 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Takara Bio Usa, Inc. | San Jose, CA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Bio Rad Laboratories Inc. | Hercules, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Boca Biolistics, LLC | Pompano Beach, FL | 238990 All Other Specialty Trade Contractors |
| Gen-Probe Incorporated | Marlborough, MA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| The Binding Site. Inc. | San Diego, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Invivoscribe, Inc., a for-profit manufacturer of precision diagnostics and molecular testing products based in San Diego, California, supplies biological kits, reagents, assays, and in-vitro diagnostic materials to federal research and medical agencies as a prime contractor (100% of recent awards), competing exclusively in full-and-open procurements with no set-aside designations across its entire footprint.
Invivoscribe's federal customer base is heavily concentrated with a single agency. The National Cancer Institute (NCI), a component of the Department of Health and Human Services, accounts for 41 awards and $668 thousand combined potential value, representing 56% of all awards and 88% of combined potential value in the source data. The Department of Veterans Affairs Veterans Health Administration, the Administration for Children and Families, and the Army Medical Command round out the customer set but with minimal exposure — three orders from Army Medical Command and one order each from VA and ACF. NCI has relied on Invivoscribe continuously since at least 2009, utilizing the vendor's IGH/IGK clonality assays and biological kits to support the Molecular Diagnostics Laboratory's CLIA and College of American Pathology-certified cancer research and diagnostics operations.
The award portfolio is characterized by small, repetitive purchase orders. Invivoscribe's combined potential value across all 73 awards totals $762 thousand, with individual orders ranging from $13,210 to $57,435 — a pattern of recurring consumables rather than large-dollar system or service contracts. The primary NAICS codes are In-Vitro Diagnostic Substance Manufacturing (35 awards) and Biological Product Manufacturing, with corresponding PSC codes for Drugs and Biologicals (30 awards) and Laboratory Equipment and Supplies (14 awards). Recent activity shows a flat trajectory: four awards in 2022 and 2023, five in 2024, three in 2025, and two in 2026 year-to-date. Two awards with combined potential value of $114 thousand reach ultimate completion inside the next twenty-four months and therefore face recompete exposure in that window.
The source identifies Invivoscribe as the sole responsible source for NCI's specialized assays, which has enabled both competitive and sole-source awards — a March 2026 purchase order for $57,435 for IGH+IGK B-cell clonality assays was issued as non-competitive sole-source under 10 USC 2304(c)(1) due to the vendor's specialized expertise, while a July 2026 order for $56,857 in IGH+IGK clonality mega-ABI diagnostic materials competed under Total Small Business set-aside rules. Invivoscribe operates with no federal contract vehicles, IDIQs, GWACs, or BPAs in the source data; all awards are direct purchase orders from customer agencies.
SBA capabilities narrative
We offer clinical laboratories, pharmaceutical companies, physicians, patients, and researchers high quality, reliable, and innovative molecular diagnostic solutions. These solutions range from CDx biomarker identification and patient stratification to assay development and reagent manufacturing, to the commercialization of these assays either as services at our harmonized clinical laboratories or as kits available to laboratories in over 700 countries.
Quick answers
Is Invivoscribe, Inc. registered in SAM.gov?
Yes. Invivoscribe, Inc.'s SAM.gov registration is active through February 3, 2027.
What is Invivoscribe, Inc.'s CAGE code?
Invivoscribe, Inc.'s CAGE code is 455H0, and its Unique Entity ID (UEI) is R1EVMK8MEZS9.
How much has Invivoscribe, Inc. received in federal contracts?
Federal contracts obligated $72,167 to Invivoscribe, Inc. in fiscal year 2025 and $323,025 in fiscal years 2023 through 2027.
What is Invivoscribe, Inc.'s most recent federal award?
Invivoscribe, Inc.'s most recent federal contract award is NCI (75N98026P00913), from Office of Logisitics and Acquisition Operations (NIH), on July 2, 2026.
On GovTribe
See Invivoscribe, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors